Entry Point Capital, LLC Pliant Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 18,323 shares of PLRX stock, worth $55,152. This represents 0.11% of its overall portfolio holdings.
Number of Shares
18,323
Previous 15,911
15.16%
Holding current value
$55,152
Previous $178,000
35.39%
% of portfolio
0.11%
Previous 0.1%
Shares
4 transactions
Others Institutions Holding PLRX
# of Institutions
175Shares Held
64.8MCall Options Held
228KPut Options Held
772K-
Deep Track Capital, LP Greenwich, CT5.97MShares$18 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$15 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.63MShares$13.9 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.23MShares$9.72 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.2MShares$9.62 Million1.61% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $147M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...